Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS One, 3(4), e2043. presented at the 2008 Apr 30. doi:10.1371/journal.pone.0002043. (2008).
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One, 4(2), e4401. presented at the 2009. doi:10.1371/journal.pone.0004401. (2009).
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One, 5(9), e12873. presented at the 2010 Sep 21. doi:10.1371/journal.pone.0012873. (2010).
Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis, 201(5), 720-9. presented at the 2010 Mar. doi:10.1086/650492. (2010).
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Hum Vaccin Immunother, 8(5), 630-8. presented at the 2012 May. doi:10.4161/hv.19454. (2012).
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. J Infect Dis, 215(1), 95-104. presented at the 2017 Jan 01. doi:10.1093/infdis/jiw500. (2017).